Beach

OTC-BB: PVCT

Cancer stocks are a dime a dozen these days with countless companies that have failed – some that failed at FDA trials and others simply because they never really developed a quality candidate in the first place. Investors knowledgeable in this field may recognize names like Genta’s GenaSense drug that failed three times during FDA trials and countless others that never even made it to that stage before running out of money. So, where are the quality companies in this space?

I will introduce you to an innovative new company that is taking a different approach by using an existing substance and repurposing it to fight cancer. This has helped it fast-track through FDA trials that test safety, while preliminary results from its efficacy trials also show great promise! Below we’ll take a look at its drug candidates, the clinical trial results, and why this stock could make a great high-risk, high-reward addition to your stock portfolio.

Provectus Pharmaceuticals, Inc. (OTC-BB: PVCT) is the company and its promising Phase 2 trial results and potential to fast-track its drug approvals make it a compelling opportunity for investors looking for a high-risk, high-reward play on a cancer drug!

A Little Background...

Test Tubes

Provectus Pharmaceuticals was formed by three scientists based in Knoxville, TN focused on developing Rose Bengal (RB) based drugs for the treatment of cancer and dermatology. The existing rose bengel compound appears to target rapidly growing cells with few side effects, robust efficacy, and appears to work with the immune system to combat them.

While many scientists have dismissed the possibility of using the body’s own immune system to combat cancer, Provectus scientists believe that this is the solution, and their preliminary data is beginning to show great promise in both oncology and dermatology fields. By thinking outside of the box, these scientists may have struck gold in the form of RB!

Want to Learn More? Receive a FREE Investor Kit!

Name: Email: Phone:

Provectus' Promising Pipeline

PV-10 for Oncology

Provectus plans on demonstrating broad spectrum efficacy for a number of cancer indications, including melanoma, breast cancer, and liver cancer.

The 10% RB solution is directly injected into tumors and may stimulate an immune system response that could combat the cancer. Preliminary tests in melanoma patients showed that the drug is well-tolerated and elicited a robust response in a majority of patients.

The company’s lead candidate is a Phase 2 indication for metastatic melanoma, with Phase 1 trials already in progress for breast carcinoma and liver mets.

PH-10 for Dermatology

Provectus plans on demonstrating the effectiveness of its drug on psoriasis and atopic dermatitis (eczema) for pharma licensure.
The 0.001% RB topical gel is applied directly to the skin and activated by visible (green) light.

Preliminary testing showed robust positive responses in 94% of patients with virtually no systemic uptake or side effects.

These dermatology indications will be commercialized first in order to generate the funding necessary to fully and effectively commercialize its potentially-blockbuster cancer treatment drugs.

Near-term Catalysts Could Jump the Stock!

During the next year, Provectus will be focused on establishing paths to licensure and business development, which is where the big money contracts typically start to come in the door. Within this next year alone…

  1. The company plans a Phase 3 follow-up and fast-track or will skip Phase 3 by using accelerated approval for its potentially-blockbuster melanoma drug and will then seek to establish a path to drug approval via the FDA.

  2. The company will continue its liver cancer studies and expand its compassionate use program in order to further demonstrate efficacy at a rapid pace.

  3. The company plans to complete its expanded Psoriasis/Eczema trials and complete pharma licensure talks at an appropriate valuation.

Assuming that the company’s plans with the Psoriasis/Eczema trials go well and it is able to license the drugs, it will not have to raise additional funds to complete the development of its oncology drugs either! This means that there could be a lot of upside with very little potential downside, especially given the success of their clinical trials to date.

Quick Links

Download Annual Report

Download Annual Report

Download Annual Report

Download Annual Report


Request an Investor Kit

Name:

Email:  

Phone:


Management Team

CEO

CEO Craig Dees, Ph.D.

Craig Dees, Ph.D., has spent more than 20 years in senior management positions at Photogen Technologies, Inc.; the Oak Ridge National Laboratory; LipoGen, Inc.; and TechAmerica, Inc. Dees was a founder, senior scientist and founding director of Photogen before Provectus was formed.

President

President Timothy Scott, Ph.D.

Tim Scott, Ph.D., has served in senior management positions at Photogen Technologies, Inc.; Genase LLC; and the Oak Ridge National Laboratory. Holder of 16 U.S. patents, Scott was a co-founder, senior scientist, vice president and chief operating officer for Photogen Technologies. Scott also served as Photogen’s interim CEO and chairman during the company’s restructuring.

VP

VP Eric Wachter, Ph.D.

Eric Wachter, Ph.D., has served in senior management positions at Photogen Technologies and the Oak Ridge National Laboratory. A holder of 16 U.S. patents, he was a co-founder of Photogen Technologies and served the company as a director, secretary, vice president and senior scientist.

CFO

CFO Peter Culpepper, MBA, CPA

Pete Culpepper has spent 20 years in the financial field working for a wide range of companies and industries in the U.S. and abroad, especially high-growth startups. His experience with for-profit companies ranges from private start-ups to publicly traded, global conglomerates. He also has worked with large non-profits and a national CPA accounting firm.

TheOTCInvestor.com (herein referred to as “us”, “we” or “the website”) is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Furthermore, investing in such securities involves substantial risk of loss and investors should seek advice from financial professionals before investing.

Our Content

TheOTCInvestor.com, the owner, publisher, editor and their associates work diligently to ensure that all facts are correct and free from error, but we are not responsible for errors and omissions. TheOTCInvestor.com and its associates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice.

Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that the investor’s entire investment may be lost or impaired due to the speculative nature of the companies listed.

TheOTCInvestor.com makes no recommendation that the securities of the companies listed should be purchased, sold or held by individuals or entities that learn of the listed companies through TheOTCInvestor.com.

Readers are encouraged to consult a broker before purchasing or selling any securities mentioned on TheOTCInvestor.com. We recommend that readers use the information found within its properties as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. TheOTCInvestor.com is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.

Safe Harbor Statement

This website contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements in connection with any discussion of future operating or financial performance are identified by use of words such as “may,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning. Such statements are based on our expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements.

Any statements that express or involve predictions, expectations, plans, beliefs, objectives, projections, future events, goals, or performance may be forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, intense competition, adverse economic conditions, termination of contracts or agreements, inadequate capital, lack of meaningful research results, inability to carry out research and development plans, loss of key personnel, and other risks detailed in the reports filed by the Securities and Exchange Commission by companies that are featured on our properties.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this website or in any document accessible from this website might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this posting or the date of the document(s) accessible from this website. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein. More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at http://www.sec.gov, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549.

Third Party Links

TheOTCInvestor.com and our newsletter may provide hyperlinks to third party websites or access to third party content. We do not control, endorse or guarantee content found in such sites. By accessing, viewing or using the website or communications originating from the website, you agree that TheOTCInvstor.com, operators, owners and employees, are not responsible for any content, associated links, resources or services associated with a third party website.

Compensation

TheOTCInvestor.com may receive compensation from companies listed or from firm’s working on behalf of the companies listed in the “Research” section of our website. If such compensation is presented, a notice will appear at the end of the affected article. The nature and amount of compensation can be found at the bottom of this disclaimer. TheOTCInvestor.com and its officers, directors and employees may also have bought or sold or may buy or sell shares in the companies discussed within the website. View Full Disclaimer

Your Agreement

By viewing or using this website, you agree to hold TheOTCInvestor.com, its operators, owners and employees, and furthermore, you agree to completely release TheOTCInvestor.com, its operators, owners and employees from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise) or injury (monetary or otherwise) that you may incur.